Showing results (431-440 of 474) with videos related to

Sort By:
Pageof 48
Vaccine|September 30, 2023
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022Meagan C Fitzpatrick, Rachel S Laufer, Ranju Baral, et al.
Vaccine|April 21, 2026
Vaccine value profile for severe fever with thrombocytopenia syndrome (SFTS)Laura Skrip, Arata Hidano, Yong Poovorawan, et al.
BMC Medicine|June 20, 2024
Healthcare utilisation in people with long COVID: an OpenSAFELY cohort studyLiang-Yu Lin, Alasdair D Henderson, Oliver Carlile, et al.
Pharmacoeconomics|October 19, 2015
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics CommunityBernhard Ultsch, Oliver Damm, Philippe Beutels, et al.
Plos Medicine|January 24, 2023
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling studyAllison Portnoy, Rebecca A Clark, Matthew Quaife, et al.
The Lancet. Global Health|March 16, 2023
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling studyRebecca A Clark, Christinah Mukandavire, Allison Portnoy, et al.
Vaccines|April 27, 2024
The Full Value of Vaccine Assessments Concept-Current Opportunities and RecommendationsRichard G White, Nicolas A Menzies, Allison Portnoy, et al.
Lancet (London, England)|November 10, 2015
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical modelsMelissa A Penny, Robert Verity, Caitlin A Bever, et al.
Vaccines|September 28, 2024
An Application of an Initial Full Value of Vaccine Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income CountriesMelissa Ko, Collrane Frivold, Mercy Mvundura, et al.
BMC Public Health|January 7, 2023
The effectiveness of pay-it-forward in addressing HPV vaccine delay and increasing uptake among 15-18-year-old adolescent girls compared to user-paid vaccination: a study protocol for a two-arm randomized controlled trial in ChinaYifan Li, Chuanyu Qin, Shengyue Qiu, et al.
Pageof 48